SGN-2FF is a potent and orally active inhibitor of glycoprotein fucosylation, directly inhibits fucosyltransferase activity.
SGN-2FF inhibits cellular fucosylation by depletion of the fucosylation substrate GDP-fucose, as well as by direct inhibition of fucosyltransferases, leading to the production of afucosylated glycoproteins including antibodies.
SGN-2FF has antitumor activity in multiple mouse tumor models, showing substantial tumor growth delay.
SGN-2FF activates human T cells in an antigen-dependent manner, also enhanced the protective effect of a lymphoma vaccine in a syngeneic mouse model.
